EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Resistance to immune checkpoint inhibitors and the tumor microenvironment

Shusuke Kawashima, Yosuke Togashi iD

Experimental Dermatology · 2023-03 · 32 (3) · 240-249

DOI: 10.1111/exd.14716 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Experimental Dermatology, online erschienen am 08.12.2022. Verfasst von Shusuke Kawashima und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Graduate School of Medicine, Chiba University, Chiba, Japan. Hauptthemen laut MEDLINE: Neoplasms, Skin Neoplasms. Die Arbeit wurde bisher 48-mal zitiert (Crossref) und nennt 117 Literaturangaben. Gefördert von: Japan Agency for Medical Research and Development, Japan Science and Technology Agency, Japan Society for the Promotion of Science.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Immune checkpoint inhibitors (ICIs) have contributed significantly to the treatment of various types of cancer, including skin cancer. However, not all patients respond; some patients do not respond at all (primary resistance), while others experience recurrence after the initial response (acquired resistance). Therefore, overcoming ICI resistance is an urgent priority. Numerous ICI resistance mechanisms have been reported. They are seemingly quite complex, varying from patient to patient. However, most involve T‐cell activation processes, especially in the tumor microenvironment (TME). ICIs exert their effects in the TME by reactivating suppressed T cells through inhibition of immune checkpoint molecules, such as cytotoxic T‐lymphocyte antigen‐4 (CTLA‐4) and programmed cell death protein 1 (PD‐1). Thus, this review focuses on the resistance mechanisms based on the T‐cell activation process. Here, we classify the main mechanisms of ICI resistance into three categories based on (1) antigen recognition, (2) T‐cell migration and infiltration, and (3) effector functions of T cells. By identifying and understanding these resistance mechanisms individually, including unknown mechanisms, we seek to contribute to the development of novel treatments to overcome ICI resistance.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NeoplasmsSkin NeoplasmsHumansImmune Checkpoint InhibitorsTumor MicroenvironmentImmunotherapy

Stichwörter der Autor:innen

acquired resistanceantitumor immunityimmune checkpoint inhibitorsprimary resistancetumor microenvironment

Substanzen

Immune Checkpoint Inhibitors

Autor:innen und Institutionen

  • Department of Dermatology, Graduate School of Medicine, Chiba University, Chiba, Japan.
  • Chiba Cancer Center, Research Institute, Chiba, Japan.
  • Department of Tumor Microenvironment, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University, Okayama, Japan.

ORCID-Profile: Yosuke Togashi

Förderung

  • Japan Agency for Medical Research and Development
  • Japan Science and Technology Agency
  • Japan Society for the Promotion of Science

Zitieren

APA

Kawashima, S., & Togashi, Y. (2023). Resistance to immune checkpoint inhibitors and the tumor microenvironment. Experimental Dermatology, 32(3), 240-249. https://doi.org/10.1111/exd.14716

Vancouver

Kawashima S, Togashi Y. Resistance to immune checkpoint inhibitors and the tumor microenvironment. Experimental Dermatology. 2023;32(3):240-249. doi:10.1111/exd.14716

BibTeX
@article{Kawashima2023,
  author = {Kawashima, Shusuke and Togashi, Yosuke},
  title = {Resistance to immune checkpoint inhibitors and the tumor microenvironment},
  journal = {Experimental Dermatology},
  year = {2023},
  volume = {32},
  number = {3},
  pages = {240--249},
  doi = {10.1111/exd.14716}
}
Kostenlos starten →